A Phase I, Open-Label, Two-Center Trial to Investigate the Mass Balance and Metabolite Profile of TH-302 in Cancer Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2018
Price : $35 *
At a glance
- Drugs Evofosfamide (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 20 Apr 2016 Status changed from active, no longer recruiting to completed.
- 21 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 23 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.